Volume 12, Number 1—January 2006
Nonpharmaceutical Interventions for Pandemic Influenza, International Measures
Since global availability of vaccine and antiviral agents against influenza caused by novel human subtypes is insufficient, the World Health Organization (WHO) recommends nonpharmaceutical public health interventions to contain infection, delay spread, and reduce the impact of pandemic disease. Virus transmission characteristics will not be completely known in advance, but difficulties in influenza control typically include peak infectivity early in illness, a short interval between cases, and to a lesser extent, transmission from persons with incubating or asymptomatic infection. Screening and quarantining entering travelers at international borders did not substantially delay virus introduction in past pandemics, except in some island countries, and will likely be even less effective in the modern era. Instead, WHO recommends providing information to international travelers and possibly screening travelers departing countries with transmissible human infection. The principal focus of interventions against pandemic influenza spread should be at national and community levels rather than international borders.
Pandemic preparedness ideally would include pharmaceutical countermeasures (vaccine and antiviral drugs), but for the foreseeable future, such measures will not be available for the global population of >6 billion (1). Thus, in 2005, after consultations with experts, the World Health Organization (WHO) recommended nonpharmaceutical public health interventions in its updated global influenza preparedness plan (2). The recommendations are intended as guidance, not as formal WHO advice (3). Such interventions, designed to reduce exposure of susceptible persons to an infectious agent, were commonly used for infection control in previous centuries. This report (part 1) and a companion article (part 2 ) summarize the scientific data, historic experience, and contemporary observations that make up the limited evidence base for these interventions as applied to influenza. Part 1 summarizes the relevant transmission characteristics of influenza and the basis for interventions to prevent spread from 1 country to another; part 2 summarizes the basis for measures within countries at the national and community levels. Both parts are designed to be read in conjunction with WHO recommendations (2,3).
Nonpharmaceutical interventions outside of healthcare settings focus on measures to 1) limit international spread of the virus (e.g., travel screening and restrictions); 2) reduce spread within national and local populations (e.g., isolation and treatment of ill persons; monitoring and possible quarantine of exposed persons; and social distancing measures, such as cancellation of mass gatherings and closure of schools); 3) reduce an individual person's risk for infection (e.g., hand hygiene); and 4) communicate risk to the public. We discuss the first category; categories 2 and 3 are addressed in part 2. We do not address infection control measures for patient care or risk communication.
Most information on transmission of influenza viruses is based on older experimental studies, inference from observations during outbreaks, and studies with other objectives, especially the assessment of vaccine or drug efficacy. These sources have substantial limitations: investigations often used different methods, involved small numbers of persons, and reflected the behavior of influenza A and B viruses in seasonal rather than pandemic settings (the level of preexisting immunity in populations is substantially higher in seasonal epidemics). For this reason, data from young children, who presumably lack prior exposure and therefore immunity to influenza, may better reflect illness and viral shedding patterns of pandemic disease. The "infectiousness" of patients is virtually always inferred on the basis of viral shedding from the upper respiratory tract rather than from directly observed transmission, but the relationship between nasopharyngeal shedding and transmission is uncertain and could vary. Detailed studies of lower respiratory tract virus loads, particularly relevant to small-particle aerosol transmission during coughing and sneezing, are not available. In many studies, the preexisting influenza antibody status of study participants is not reported, even though this factor is critical in influencing illness and viral shedding patterns. In controlled studies, in which susceptible study participants are typically screened for preexisting influenza antibody by hemagglutination inhibition assays to the challenge virus, the routes of infection and the challenge virus can differ. Other factors that differ among studies are the age and preexisting medical conditions of study participants and the timing of specimen collections for virus testing.
Viral Shedding and Transmission by Persons with Symptoms
In otherwise healthy adults with influenza infection, viral shedding 24–48 h before illness onset has been detected but generally at much lower titers than during the symptomatic period (Table A1). Titers of infectious virus peak during the first 24–72 h of illness (103–107 50% tissue culture infective dose [TCID50]/mL nasopharyngeal wash) and decline within several days, with titers usually low or undetectable by day 5. Shedding in highly immunocompromised persons may last weeks to months. Compared with adults, children can shed virus earlier before illness begins and for longer periods once illness starts. As in adults, peak shedding in children occurs during the first 1–3 days of illness, but absolute levels may be higher than those in adults. In 1 report, at least 4 illnesses (8% of the total) in children were associated with presymptomatic shedding that began 6, 4, 3, and 3 days, respectively, before illness onset (5). The median duration of virus detection is typically 7–8 days after illness onset, but shedding for up to 21 days has been recorded. In 1 study, virus was shed by 10% of children on days 8–11, by 5% on days 12–15, and by 0% on days 16–19 (6). Infants with infection requiring hospitalization may shed virus longer. In both adults and children, shedding does not usually continue once illness has resolved. Serologic testing indicates that ≈30%–50% of seasonal influenza infections may not result in illness.
Viral Shedding and Transmission by Infected Persons without Symptoms
During the incubation period, persons with presymptomatic influenza infection shed virus at lower titers than persons with symptoms (Table A1); however, the infectiousness of those with presymptomatic infection has not been studied. Apparently the only published report implicating transmission during the incubation period involves a group of adults in New Zealand in 1991. Of 26 adults who bagged fertilizer for 8 h, influenzalike illness (fever, headache, sore throat, myalgia, respiratory symptoms) developed in 16 and mild, "cold-like" illnesses developed in 3 persons within 24 to 48 h after working with the fertilizer. A person considered to be the probable index patient had felt unwell during work, although he did not have respiratory symptoms; an influenzalike illness began to develop 6 h after he finished work. Influenza A virus H1N1 was isolated from 2 symptomatic persons; whether these included the suspected index patient and whether that person transmitted infection during an incubation period or the cluster resulted from community exposure are unknown. The group shared drinking bottles and worked in a dusty environment, both of which could have facilitated transmission (7).
Large-Droplet and Aerosol Respiratory Transmission
Animal studies and most influenza outbreaks among humans suggest that virus-laden large droplets (particles >5 mm in diameter) generated when infected persons cough or sneeze are the predominant mechanism of influenza virus transmission (8). However, evidence for aerosol spread (especially in unventilated conditions) is available (9). Although a direct comparison has not been made, experimental studies suggest that the infectious dose for humans exposed by aerosol is lower than that seen with experimental nasopharyngeal instillation (10). The precise proportion of infections transmitted by large droplets versus aerosols is difficult to assess and likely depends on the setting but is relevant when developing recommendations on mask use. Data do not exist to quantify the relative efficacy of surgical masks versus respirators in preventing influenza infections in exposed persons, but surgical masks should protect against large droplets, believed to be the major mode of transmission (8).
Transmission by Contaminated Hands, Other Surfaces, or Fomites
Transmission of influenza viruses by contaminated hands, other surfaces, or fomites has not been extensively documented but is believed to occur. In a nursing home outbreak in Hawaii, an investigation concluded that transmission of oral secretions from patient to patient by staff who were not gloved best explained the outbreak (11). In an environmental survival study, influenza A virus placed on hard, nonporous surfaces (steel and plastic) could be cultured from the surfaces at diminishing titer for <24 to 48 h and from cloth, paper, and tissues for <8 to 12 h at conditions of 35% to 40% humidity and a temperature of 28°C (12). Higher humidity shortened virus survival. Virus on nonporous surfaces could be transferred to hands 24 h after the surface was contaminated, while tissues could transfer virus to hands for 15 min after the tissue was contaminated. On hands, virus concentration fell by 100- to 1,000-fold within 5 min after transfer. The authors concluded that transmitting infection from the surfaces tested would require a high titer of virus (105.0 TCID50/mL) on the surface; such titers can be found in nasal secretions at an early stage of illness.
Incubation Period and Infectiousness
The incubation period for influenza averages 2 days (range 1–4 days), and the serial interval (the mean interval between onset of illness in 2 successive patients in a chain of transmission) is 2–4 days. Also, viral excretion peaks early in illness. These factors enable influenza to spread rapidly through communities. By contrast, severe acute respiratory syndrome (SARS) has a serial interval of 8 to 10 days, and peak infectivity does not occur until week 2 of illness, which allows more time to effectively implement isolation and quarantine measures (13). The basic reproduction number (R0, the mean number of secondary cases generated by 1 infected person in a fully susceptible population) of the 1918 pandemic influenza subtype has recently been re-estimated as ≈2–3 (14) and 1.8 (15), comparable to that of the SARS-associated coronavirus (SARS-CoV) (R0 2–4) (13).
Amplifying Groups and Settings
Children in preschool and school-age groups are frequently observed to amplify transmission (16), although any group living in close proximity can do so, and outbreaks are observed in institutions involving persons of all ages (11). Although transmission may be amplified at mass gatherings (e.g., theaters, sports events), documentation is scarce.
Experience from Earlier Pandemics
1918 Experience with Quarantine Enacted by Islands
In the 1918 pandemic, some island countries enacted maritime quarantines that appear to have delayed or prevented the introduction of pandemic influenza. Maritime quarantines were facilitated because ships had often been at sea for an extended period, reducing the likelihood of ongoing onboard infection at the time of arrival in port. Also, authorities could require ships to anchor in harbors or at quarantine stations on offshore islands, thus minimizing contact with persons on shore.
In October 1918, Australia began to quarantine arriving ships upon which a case of influenza had occurred during the voyage; the duration of quarantine was determined on the basis of the date of the most recent case. Quarantine was also applied for 7 days, even if no cases were reported, to vessels arriving from New Zealand and South Africa because of severe epidemic disease in those areas and from certain Pacific Islands with which communication was limited. Persons in quarantine had their temperature measured at least once daily, and those with an oral temperature >99°F (37.2°C) were isolated at hospitals for observation. Measures taken by hospital staff to avoid infection included the use of masks and other "routine precautions taken at isolation hospitals." Reportedly, no direct evidence of escape of infection from any vessel to the shore occurred.
From October 1918 through May 1919, a total of 79 "infected vessels" containing 2,795 patients, 48,072 passengers, and 10,456 crew and 149 "uninfected vessels" containing 7,075 passengers and 7,941 crew arrived at Australian ports (17,18). The first cases of pandemic influenza in Australia were reported in January 1919, suggesting that these measures delayed entry of the disease for ≈3 months. Although the national quarantine director believed that pandemic influenza had entered Australia before quarantine was established, this belief was not documented, and other reports indicate that some ships' officers and soldiers returning to Australia from Europe had concealed illness to avoid protracted quarantine (18). When the infection did emerge in Australia, case-fatality rates were lower than those in many places affected earlier.
According to a report from the New South Wales Department of Public Health, ships with ill passengers arrived regularly at Sydney (the state capital) from October 1918 to January 1919. Of 326 passengers or crew treated at the quarantine hospital, 49 died. Recovered patients and contacts emerging from quarantine were released into the general population and monitored by health officials for a few days to a few weeks. Two cases were in nurses who had contracted influenza while caring for patients at the quarantine hospital. "In no case did any suspicion arise that such persons had spread influenza among those with whom they had come in contact" (19). The first cases of influenza in New South Wales were in soldiers who arrived overland by train from the port city of Melbourne, Victoria, where recent cases were known to have occurred but were not promptly disclosed by the authorities (19).
In 1918, the island of Madagascar, then a French colony, also implemented a "rigorous quarantine" and did not report cases of influenza until April 1919. In contrast, nearby coastal regions of eastern and southern Africa reported cases beginning in September to December 1918. Contact between Madagascar and South Africa, where the disease was epidemic, was limited to a single coastal steamboat (20,21). In the Pacific, American Samoa implemented quarantine measures and was spared infection, while nearby islands were severely affected (22). The French colony of New Caledonia was spared infection by requiring ships to remain in quarantine at their ports of departure, a form of "exit screening," discussed below (23).
Other Quarantine Experiences
On the African mainland, quarantine was enacted in 1918 in some port cities in, for example, Liberia, Gabon, and Ghana (formerly known as the Gold Coast). Details generally are unavailable, but, on the whole, even though entry may have been delayed by some weeks, the experience was less successful than that of islands that enacted quarantine. Disease arrived from inland routes and, according to 1 report, quarantine of a ship in Accra, Ghana, known in advance to be carrying persons with influenza was not successful; disease spread to dock workers and subsequently entered the country (21,24).
In 1918, closing roads at the northern land border of Ghana was not feasible because of the volume of trade and the probability that police barriers would be evaded. An attempt was nevertheless made to close roads at the border town of Tumu, but authorities concluded that "a handful of constables could not stop the epidemic and the effort was soon abandoned" (24). In Canada and Australia, substantial measures, including police checkpoints and interruption of road and rail traffic, did not prevent or appear to delay the spread of infection between Canadian provinces or Australian states (4,18).
A WHO expert consultation on the 1957 influenza pandemic summarized the effect of quarantine measures at international borders as follows. Onset in Israel was delayed by 2 months in comparison to neighboring countries, attributed to absence of international travel with neighboring countries (for political, not quarantine reasons). In South Africa, "some delay" occurred from restrictions on ships arriving at ports, but the evidence was "less convincing." Elsewhere, "no effect was detected. It seems that if such measures are to be effective, they must be very severe…. a high price to pay for a few additional weeks freedom from the disease" (25).
Experience from Contemporary SARS and Influenza Outbreaks
In modern times, the most extensive use of nonpharmaceutical public health interventions to contain a transmissible respiratory viral infection occurred during the SARS epidemic of 2003. Some lessons learned from that experience may be applicable to influenza, although important differences exist between the epidemiologic parameters of influenza virus and SARS-CoV. The most notable of these are that influenza has a serial interval of 2 to 4 days and infectivity is maximal early in illness, whereas for SARS the serial interval is 8–10 days and infectivity peaks during week 2 of illness. These factors allow little time for instituting the isolation and quarantine interventions that were essential in controlling SARS.
Entry Screening of Air-travel Passengers during 2003 SARS Outbreak
In the 2003 SARS experience, data from 4 Asian locations and Canada indicated that body temperature–sensing devices did not detect anyone with SARS among >35 million entering travelers screened. Administration of health declarations (a questionnaire completed by the traveler to report health information, e.g., symptoms and history of exposure) to >45 million entering travelers detected 4 SARS cases. At least 31 million health alert notices were distributed to entering international travelers in several countries, but follow-up information is limited. Mainland China reported the distribution of 450,000 notices and detection of 4 SARS cases possibly linked to the notices. Thailand reported printing 1 million notices and detecting 24 cases directly linked to them (26). The 5 persons with SARS who entered Canada did not have signs or symptoms at international airports; Canadian authorities concluded that border screening for SARS was insensitive and not cost-effective and that surveillance allowing for early detection of imported cases was preferable (27).
The possible effect of entry screening for pandemic influenza has been estimated for the United Kingdom, with the assumption that exit screening is in place at international airports in countries with pandemic influenza. A mean of 9% of persons infected by influenza who were asymptomatic on departure would be estimated to develop influenza symptoms en route to the United Kingdom; the percentage would be higher during longer flights. Symptoms would develop in an estimated mean of 17% (range 12%–23%) of infected persons traveling from Asian cities. Airplanes that arrive daily at 12 airports in the United Kingdom from the Far East have >12,000 seats; entry screening would fail to detect ≈83% of infected persons (28). Travelers arriving on connecting flights were not considered. In Taiwan during the 2003 SARS outbreak, 80,813 incoming air-travel passengers from affected areas were quarantined; 21 (0.03%) were diagnosed with suspected or probable SARS. None of these 21 cases had been detected by entry screening (26,29). Another modeling study from the UK Health Protection Agency suggests that reduction of air travel to and from affected areas, if implemented, must be almost total and nearly instantaneous to delay pandemic spread significantly (B. Cooper, pers. comm.).
Exit Screening of Travelers during SARS Outbreak
After WHO recommended exit screening of international travelers departing from affected areas on March 27, 2003, no additional spread of SARS through air travel was documented from countries with exit screening. This finding may reflect a deterrence effect, a generally low incidence of SARS cases, or both. Combined data from several countries indicate 1 case detected among 1.8 million departing passengers completing health questionnaires and no cases among 7 million persons who underwent thermal scanning on departure (26).
Measures To Limit Influenza Virus Transmission on Conveyances
Influenza has been transmitted on airplanes (30) and ships (31). In 1 cluster, influenzalike illness developed in 72% of passengers seated in an airplane that was on the ground for 3 h without ventilation and that held a person with symptomatic influenza (9). On a 75-seat aircraft, 15 passengers traveling with an influenza-infected person became ill. All 15 persons were seated within 5 rows of the index patient, and 9 were seated within 2 rows (32).
In a review of the Australian experience with pandemic influenza aboard ships in 1918 to 1919, a "Daily thermometer parade and removal of any person febrile or reporting sick (was) most thoroughly and efficiently carried out" (17). Despite these measures, examples were given of 3 ships with 89%, 46%, and 30%, respectively, of those onboard who were ill, which led to the "conclusion that neither inhalation, inoculation, nor isolation of the sick would stop an epidemic. . . . No administrative measure was successful in modifying the time factor of a shipboard epidemic, although there is some reason for believing that the measures employed were, by their combined influence, successful in reducing the potential volume of actual cases" (17).
Influenza outbreaks have been reported on cruise ships during international voyages (31). A large summertime outbreak involved both international travelers and crew during 3 cruises of 1 ship. Control measures included surveillance, isolation of ill crew, immunization of the crew, and use of antiviral drugs for treatment and prophylaxis of crew and passengers (31,33).
During the 2003 SARS outbreak, the disease was transmitted on and spread internationally via aircraft. The most extensive investigation included 3 flights on which an index passenger had SARS; on 1 of these flights, 22 (18.3%) of 120 other passengers and crew became infected. A higher risk was noted for passengers seated near the index patient, but most passengers who became infected were seated farther away, even though their individual risk was lower (34). In most other investigations, no transmissions were documented, although the investigations were limited (26).
The effectiveness of nonpharmaceutical public health interventions in affecting the spread of pandemic influenza depends on transmission characteristics of the virus. If a substantial proportion of transmission occurs during the incubation period or during asymptomatic infection, the population impact of health screening and case-patient isolation will be diminished. The age distribution of patients is also important: if children play a central role in initial community transmission, school closure would likely be more effective. Since a new pandemic subtype might have different transmission characteristics than previous subtypes, these characteristics and associated illness patterns must be assessed in the field as soon as human-to-human transmission begins. Monitoring over time is also needed to assess possible changes as the virus becomes more adapted to human hosts.
WHO has developed recommendations to provide guidance until transmission characteristics can be determined. The recommendations are based on limited information, including virologic data from seasonal epidemics and volunteer studies rather than pandemics, in which shedding and transmission may be more intense and prolonged because of lack of population immunity. These data indicate that influenza viral shedding in the upper respiratory tract (and presumably also infectiousness) is correlated with fever and the severity of respiratory symptoms in both adults and children. The importance of transmission from infected persons during the incubation period or from persons with asymptomatic infection is uncertain but appears to be substantially less than from symptomatic persons. The principal difficulties in using nonpharmaceutical interventions to reduce influenza transmission among humans include the peak infectivity early in illness and the short incubation period, which both result in a short serial interval between related cases. Recent reports suggest that the 1918 virus may have been less transmissible than previously thought (R0 1.8–3), although whether public health interventions in 1918 might have affected these estimates is uncertain. If a novel human influenza subtype behaves in a manner similar to the pandemic virus of 1918–1919, available information supports the use of nonpharmaceutical interventions to delay or contain transmission during WHO phases 4 and 5 (limited human-to-human transmission) and use of different interventions to reduce the impact in phase 6 (pandemic phase) (2,3).
At the international level, experience in past influenza pandemics indicates that screening and quarantine of entering travelers at international borders did not substantially delay introduction, except in some island countries. Similar policies, even if they could be implemented in time and regardless of expense, would doubtfully be more effective in the modern era of extensive international air travel. WHO instead recommends that travelers receive health alert notices, although entry screening may be considered when the host country suspects that exit screening at the traveler's point of embarkation is suboptimal; in geographically isolated, infection-free areas (e.g., islands); and where a host country's internal surveillance capacity is limited (2).
WHO recommends consideration of exit screening by health declaration and temperature measurement for international travelers departing countries with human infection at phases 4, 5, and 6. Exit screening in affected countries is a better use of global resources: fewer persons would need to be screened, the positive predictive value for ill persons detected would be higher, and transmission on conveyances, such as aircraft, would be reduced. Exit screening is disruptive and costly, however, and will not be fully efficient as influenza viruses can be carried by asymptomatic persons who will escape detection during screening (2,3). As was true for SARS, the principal focus of WHO-recommended nonpharmaceutical interventions is not at international borders but at national and community levels (4).
- World Health Organization. Avian influenza: assessing the pandemic threat. 2005 [cited 2005 Jan]. Available from http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index.html
- World Health Organization. WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics. Annex 1. 2005 [cited 2005 Apr]. Available from http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5/en
- World Health Organization. Non-pharmaceutical interventions: their role in reducing transmission and spread. 2005 [cited 2005 Nov]. Available from http://www.who.int/csr/disease/avian_influenza/pharmaintervention2005_11_3/en/index.html
- World Health Organization Writing Group. Nonpharmaceutical public health interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006;12:88–94.
- Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433–41.
- Hall CB, Douglas RG Jr, Geiman JM, Meagher MP. Viral shedding patterns of children with influenza B infection. J Infect Dis. 1979;140:610–3.
- Sheat K. An investigation into an explosive outbreak of influenza—New Plymouth. Communicable Disease New Zealand. 1992;92:18–9.
- Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis. 2003;37:1094–101.
- Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol. 1979;110:1–6.
- Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med. 1966;122:800–4.
- Morens DM, Rash VM. Lessons from a nursing home outbreak of influenza A. Infect Control Hosp Epidemiol. 1995;16:275–80.
- Bean B, Moore BM, Sterner B, Peterson LR, Gerding DN, Balfour HH Jr. Survival of influenza viruses on environmental surfaces. J Infect Dis. 1982;146:47–51.
- World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2003 [cited 2005 Oct 27]. p. 25–27. Available from http://www.who.int/csr/sars/en/WHOconsensus.pdf
- Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904–6.
- Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437:209–14.
- Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156:986–91.
- Cumpston JHL. Influenza and maritime quarantine in Australia. Report no. 18. Melbourne: Commonwealth of Australia, Quarantine Service; 1919.
- McQueen H. "Spanish 'flu"—1919: political, medical and social aspects. Med J Aust. 1975;1:565–70.
- New South Wales Department of Public Health. Report on the influenza epidemic in New South Wales in 1919. Section V. Sydney: William Applegate Gullick; 1920. p 139–272.
- Camail. In: Huot. L'épidémie d'influenza de 1918–1919 dans les colonies françaises. 3. Colonies de la côte orientale d'Afrique. Madagascar. Annales de Médecine et Pharmacie Coloniales. 1921;19:463–5.
- Patterson KD, Pyle GF. The diffusion of influenza in sub-Saharan Africa during the 1918–1919 pandemic. Soc Sci Med. 1983;17:1299–307.
- Barry JM. The great epidemic: the epic story of the deadliest plague in history. New York: Viking Penguin; 2004.
- Peltier. L'épidémie d'influenza qui a sévi en Nouvelle Calédonie en 1921. Bulletin de l'Office International d'Hygiène Publique. 1922;14:676–85.
- Patterson KD. The influenza epidemic of 1918–1919 in the Gold Coast. J Afr Hist. 1983;24:485–502.
- World Health Organization. Expert committee on respiratory virus disease: first report. World Health Organ Tech Rep Ser. 1959;58:1–59.
- Bell DM; World Health Organization Working Group on Prevention of International and Community Transmission of SARS. Public health interventions and SARS spread, 2003. Emerg Infect Dis. 2004;10:1900–6.
- St John RK, King A, de Jong D, Bodie-Collins M, Squires SG, Tam TW. Border screening for SARS. Emerg Infect Dis. 2005;11:6–10.
- Pitman RJ, Cooper BS, Trotter CL, Gay NJ, Edmunds WJ. Entry screening for SARS or influenza, policy evaluation. BMJ. 2005;331:1242–3.
- Centers for Disease Control and Prevention. Use of quarantine to prevent transmission of severe acute respiratory syndrome—Taiwan, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:680–3.
- Mangili A, Gendreau MA. Transmission of infectious diseases during commercial air travel. Lancet. 2005;365:989–96.
- Miller JM, Tam TW, Maloney S, Fukuda K, Cox N, Hockin J, Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis. 2000;31:433–8.
- Marsden AG. Influenza outbreak related to air travel. Med J Aust. 2003;179:172–3.
- Centers for Disease Control and Prevention. Preliminary guidelines for the prevention and control of influenza-like illness among passengers and crew members on cruise ships. 1999 [cited 2005 Sep]. Available from http://www.cdc.gov/travel/CDCguideflufnl.pdf
- Olsen SJ, Chang HL, Cheung TY, Tang AF, Fisk TL, Ooi SP, Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med. 2003;349:2416–22.
- Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433–41.
- Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987;80:275–82.
- Davis DJ, Philip RN, Bell JA, Vogel JE, Jensen DV. Epidemiologic studies on influenza in familial and general population groups. 1951–1956. III. Laboratory observations. Am J Hyg. 1961;73:138–47.
- Foy HM, Cooney MK, Allan ID, Albrecht JK. Influenza B in households: virus shedding without symptoms or antibody response. Am J Epidemiol. 1987;126:506–15.
- Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis. 1973;128:479–87.
- Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis. 1971;124:473–80.
- Khakpour M, Saidi A, Naficy K. Proved viraemia in Asian influenza (Hong Kong variant) during incubation period. BMJ. 1969;4:208–9.
- Philip RN, Bell JA, Davis DJ, Beem MO, Beigelman PM, Engler JI, Epidemiologic studies on influenza in familial and general population groups, 1951–1956. II. Characteristics of occurrence. Am J Hyg. 1961;73:123–37.
- Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness. XIII. Influenza infection and disease, 1976–1981. Am J Epidemiol. 1985;121:811–22.
- Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998;101:643–9.
TableCite This Article
1The writing group was established by request of the WHO Global Influenza Programme. It consisted of the following persons: David Bell, Centers for Disease Control and Prevention, Atlanta, Georgia, USA (coordinator); Angus Nicoll, European Centre for Disease Prevention and Control, Stockholm, Sweden, and Health Protection Agency, London, United Kingdom (working group chair); Keiji Fukuda, WHO, Geneva, Switzerland; Peter Horby, WHO, Hanoi, Vietnam; and Arnold Monto, University of Michigan, Ann Arbor, Michigan, USA. The following persons made substantial contributions: Frederick Hayden, University of Virginia, Charlottesville, Virginia, USA; Clare Wylks and Lance Sanders, Australian Government Department of Health and Ageing, Canberra, Australian Capital Territory, Australia; and Jonathan Van Tam, Health Protection Agency, London, United Kingdom.